oral antiviral therapy

来源: 于 2021-09-01 18:51:19 [旧帖] [给我悄悄话] 本文已被阅读：次
  • Pfizer Inc (NYSE: PFE) has started dosing in Phase 2/3 trial of its oral antiviral therapy for COVID-19 in non-hospitalized, symptomatic adult patients.
  • The trial would enroll 1,140 participants who will receive PF07321332/ritonavir combo or placebo every 12 hours for five days.
  • PF-07321332 is designed to block the activity of a key enzyme that is needed for the coronavirus to replicate.